Jingxin Pharmaceutical is a private company. Jingxin Pharmaceutical refers to Zhejiang Jingxin Pharmaceutical Co., Ltd., whose predecessor can be traced back to 1990 as a joint venture between Xinchang Capsule Factory and Beijing No. 3 Pharmaceutical Factory. After many institutional reforms and equity changes, the company was finally successfully listed on the Shenzhen Stock Exchange on July 15, 2004, with the stock code 002020. Since its listing, the company has relied on its strong R&D strength and marketing capabilities to continuously expand its product line and increase its market share.
Business Scope and Products
Jingxin Pharmaceutical’s business scope covers many fields such as raw materials, preparations and medical devices. The company has a rich product line, including ciprofloxacin hydrochloride, levofloxacin hydrochloride and other raw materials, as well as a variety of finished pharmaceutical dosage forms such as tablets, capsules, large-volume injections, etc. With their excellent quality and efficacy, these products are popular in Southeast Asia, South Asia, Latin America, Europe and other international markets.
Jingxin Pharmaceutical is also committed to the R&D and production of medical devices. Through its wholly-owned subsidiary Shenzhen Jufeng Display Technology Co., Ltd., it provides professional medical imaging solutions, further broadening the company's business scope.
R&D strength and innovation
Jingxin Pharmaceutical attaches great importance to R&D and innovation, and has multiple scientific research institutions such as postdoctoral research workstations and provincial technology centers. The company has established long-term and close technical cooperation relationships with a number of national pharmaceutical research institutions and famous universities, and continues to cultivate and improve the company's technological innovation capabilities and scientific research levels through various methods such as independent research and development and joint development. The company already has 8 national key new products and has undertaken 9 National Torch Plan projects.
Social Responsibility and Corporate Honor
Social Responsibility: While pursuing economic benefits, Jingxin Pharmaceutical also actively fulfills its social responsibilities. The company adheres to the mission of "carefully guarding health" and is committed to providing patients with safe and effective drugs and medical devices.
Enterprise Honors: Top 100 Enterprises in China's Pharmaceutical Industry, Top 20 Innovative Pharmaceuticals in China, China Patent Gold Award, Leading Enterprise in the Internationalization of National Pharmaceutical Enterprise Preparations, First Prize of Zhejiang Province Science and Technology Progress Award, Zhejiang Province No. A group of innovative leading enterprises, national key high-tech enterprises, national enterprise technology centers, the first batch of "leading enterprises in the internationalization of preparations for Chinese pharmaceutical enterprises", postdoctoral scientific research workstations, provincial key enterprise research institutes, and provincial high-tech enterprise R&D centers , provincial academician expert workstation, passed the US FDA on-site certification, passed the German GMP certification, one of the top ten leading brands of Chinese medicine, and a national intellectual property advantage enterprise.
Future expectations of the company
Jingxin Pharmaceutical will continue to adhere to the business policy of "strengthening the main pharmaceutical business and developing medical devices", with the mission of "carefully guarding health" and becoming China's leading pharmaceutical company. A leader in the fields of neuropsychiatry, cardiovascular and cerebrovascular diseases. By continuously increasing R&D investment, optimizing product structure, and expanding international markets, Jingxin Pharmaceutical is expected to achieve more brilliant development in the future.